SEC Comment Letter 0000000000-25-001295 to FibroBiologics, Inc. (FBLG)
FibroBiologics, Inc.
Date: Feb. 6, 2025 · CIK: 0001958777 · Accession: 0000000000-25-001295
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284663
Letter
February 6, 2025 Pete O’Heeron Chief Executive Officer FibroBiologics, Inc. 455 E. Medical Center Blvd. Suite 300 Houston, Texas 77598 Re:FibroBiologics, Inc. Registration Statement on Form S-3 Filed February 3, 2025 File No. 333-284663 Dear Pete O’Heeron: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jeremy W. Cleveland
Show Raw Text
February 6, 2025
Pete O’Heeron
Chief Executive Officer
FibroBiologics, Inc.
455 E. Medical Center Blvd.
Suite 300
Houston, Texas 77598
Re:FibroBiologics, Inc.
Registration Statement on Form S-3
Filed February 3, 2025
File No. 333-284663
Dear Pete O’Heeron:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jeremy W. Cleveland